CL2012001696A1 - Método para disminuir la inmunogenicidad de dominios variables de anticuerpos que comprende el paso de sustituir uno o mas residuos de amino ácidos localizados en la interfaz entre la cadena variable y la cadena constante de un anticuerpo de longitud completa. - Google Patents

Método para disminuir la inmunogenicidad de dominios variables de anticuerpos que comprende el paso de sustituir uno o mas residuos de amino ácidos localizados en la interfaz entre la cadena variable y la cadena constante de un anticuerpo de longitud completa.

Info

Publication number
CL2012001696A1
CL2012001696A1 CL2012001696A CL2012001696A CL2012001696A1 CL 2012001696 A1 CL2012001696 A1 CL 2012001696A1 CL 2012001696 A CL2012001696 A CL 2012001696A CL 2012001696 A CL2012001696 A CL 2012001696A CL 2012001696 A1 CL2012001696 A1 CL 2012001696A1
Authority
CL
Chile
Prior art keywords
chain
variable
amino acid
acid residues
antibody
Prior art date
Application number
CL2012001696A
Other languages
English (en)
Inventor
Leonardo Borras
David Urech
Tea Gunde
Original Assignee
Esbatech And Alcon Biomedical Reserch Unit Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech And Alcon Biomedical Reserch Unit Llc filed Critical Esbatech And Alcon Biomedical Reserch Unit Llc
Publication of CL2012001696A1 publication Critical patent/CL2012001696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Método para disminuir la inmunogenicidad de dominios variables de anticuerpos que comprenden una cadena liviana variable <em>y/o </em>una cadena pesada variable, donde e) método comprende el paso de sustituir uno o más residuos de amino ácidos de la cadena liviana varIable y/o la cadena pesada varIable, estando dicho residuo presente en la interfaz entre la cadena variable y la cadena constante de un anticuerpo de longitud complete correspondiente. donde los uno o más residuos de amino ácidos de la cadena pesada variable están en una o más de las siguientes posIciones 12, 97, 98. 99, 103 y/o 144 (numeración AHo), y donde los uno o más residuos de amino ácidos de la cadena liviana variable están en las posiciones 99, 101 y/o 148 (numeración AHo).
CL2012001696A 2009-12-23 2012-06-21 Método para disminuir la inmunogenicidad de dominios variables de anticuerpos que comprende el paso de sustituir uno o mas residuos de amino ácidos localizados en la interfaz entre la cadena variable y la cadena constante de un anticuerpo de longitud completa. CL2012001696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28944609P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
CL2012001696A1 true CL2012001696A1 (es) 2013-03-08

Family

ID=43733894

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001696A CL2012001696A1 (es) 2009-12-23 2012-06-21 Método para disminuir la inmunogenicidad de dominios variables de anticuerpos que comprende el paso de sustituir uno o mas residuos de amino ácidos localizados en la interfaz entre la cadena variable y la cadena constante de un anticuerpo de longitud completa.

Country Status (16)

Country Link
US (4) US8796425B2 (es)
EP (3) EP4219545A1 (es)
JP (6) JP5914353B2 (es)
KR (3) KR20170084357A (es)
CN (2) CN102686608A (es)
AR (1) AR079700A1 (es)
AU (1) AU2010335950B2 (es)
BR (1) BR112012017051A2 (es)
CA (1) CA2777527C (es)
CL (1) CL2012001696A1 (es)
MX (2) MX2012005345A (es)
RU (1) RU2585534C2 (es)
TW (3) TWI633184B (es)
UY (2) UY39290A (es)
WO (1) WO2011075861A1 (es)
ZA (4) ZA201202299B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11427632B2 (en) 2016-07-06 2022-08-30 Celgene Corporation Antibodies with low immunogenicity and uses thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856480B2 (ja) * 2008-06-25 2016-02-09 エスバテック − ア ノバルティスカンパニー エルエルシー 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化
ES2861592T3 (es) * 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
KR101671886B1 (ko) * 2008-06-25 2016-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
BR112012017051A2 (pt) * 2009-12-23 2017-12-05 Esbatech Alcon Biomed Res Unit método para diminuir a imunogenicidade
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
MX350074B (es) * 2011-06-23 2017-08-25 Ablynx Nv Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina.
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
DK3143403T3 (da) 2014-05-16 2022-01-17 Ablynx Nv Fremgangsmåder til påvisning og/eller måling af anti-lægemiddelantistoffer, især behandlingsinducerede anti-lægemiddelantistoffer
RS60717B1 (sr) 2014-05-16 2020-09-30 Ablynx Nv Varijabilni domeni imunoglobulina
CN108350069B (zh) * 2015-10-30 2021-11-12 埃博灵克斯股份有限公司 针对il-23的多肽
KR20180081825A (ko) 2015-12-04 2018-07-17 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
UA125761C2 (uk) 2017-05-31 2022-06-01 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, який перешкоджає передачі wnt-сигналів у пухлинних клітинах
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
AU2019280900A1 (en) 2018-06-09 2020-11-19 Boehringer Ingelheim International Gmbh DLL3-CD3 bispecific antibodies
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2023110190A1 (en) 2021-12-13 2023-06-22 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
EP4273162A1 (en) 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2023214047A1 (en) 2022-05-06 2023-11-09 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3881593A (en) 1992-03-18 1993-10-21 Biomira Inc. Selective alteration of antibody immunogenicity
DE69726003T2 (de) 1996-07-16 2004-08-26 Andreas Plückthun Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
CA2438513C (en) * 2001-02-19 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified anti-egfr antibodies with reduced immunogenicity
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
KR100825156B1 (ko) 2003-08-13 2008-04-24 화이자 프로덕츠 인코포레이티드 변형된 인간 ｉｇｆ-ｉｒ 항체
SI2164961T1 (sl) * 2007-06-25 2015-05-29 Esbatech, An Alcon Biomedical Research Unit Llc InĹľeniring na osnovi zaporedij in optimizacija mono-veriĹľnih protiteles
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
US8537790B2 (en) * 2008-03-10 2013-09-17 Motorola Mobility Llc Hierarchical pilot structure in wireless communication systems
ES2861592T3 (es) * 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
JP5856480B2 (ja) * 2008-06-25 2016-02-09 エスバテック − ア ノバルティスカンパニー エルエルシー 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化
CA2728829C (en) * 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
BR112012017051A2 (pt) * 2009-12-23 2017-12-05 Esbatech Alcon Biomed Res Unit método para diminuir a imunogenicidade

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11427632B2 (en) 2016-07-06 2022-08-30 Celgene Corporation Antibodies with low immunogenicity and uses thereof

Also Published As

Publication number Publication date
MX352871B (es) 2017-12-13
JP2021153603A (ja) 2021-10-07
JP5914353B2 (ja) 2016-05-11
KR20120102061A (ko) 2012-09-17
CA2777527A1 (en) 2011-06-30
TWI662128B (zh) 2019-06-11
CA2777527C (en) 2020-06-23
ZA201402145B (en) 2018-05-30
JP6815083B2 (ja) 2021-01-20
KR101721187B1 (ko) 2017-03-29
JP2019141071A (ja) 2019-08-29
KR101758703B1 (ko) 2017-07-18
TW201125975A (en) 2011-08-01
US9803027B2 (en) 2017-10-31
ZA201202299B (en) 2014-06-25
WO2011075861A1 (en) 2011-06-30
TWI633184B (zh) 2018-08-21
TW201925228A (zh) 2019-07-01
EP2516461A1 (en) 2012-10-31
ZA201706443B (en) 2020-12-23
US20180016350A1 (en) 2018-01-18
US20210214461A1 (en) 2021-07-15
RU2012130945A (ru) 2014-01-27
US8796425B2 (en) 2014-08-05
KR20170036137A (ko) 2017-03-31
CN102686608A (zh) 2012-09-19
KR20170084357A (ko) 2017-07-19
AR079700A1 (es) 2012-02-15
AU2010335950A1 (en) 2012-07-19
RU2585534C2 (ru) 2016-05-27
JP2013515460A (ja) 2013-05-09
ZA202006532B (en) 2022-04-28
US20150080555A1 (en) 2015-03-19
EP3498731A1 (en) 2019-06-19
UY39290A (es) 2021-07-30
MX2012005345A (es) 2012-06-08
CN109293768A (zh) 2019-02-01
US10781268B2 (en) 2020-09-22
AU2010335950B2 (en) 2014-08-21
US20110152505A1 (en) 2011-06-23
JP2016094487A (ja) 2016-05-26
UY33154A (es) 2011-06-30
TW201619383A (zh) 2016-06-01
JP2017121254A (ja) 2017-07-13
EP4219545A1 (en) 2023-08-02
JP2015131855A (ja) 2015-07-23
BR112012017051A2 (pt) 2017-12-05

Similar Documents

Publication Publication Date Title
CL2012001696A1 (es) Método para disminuir la inmunogenicidad de dominios variables de anticuerpos que comprende el paso de sustituir uno o mas residuos de amino ácidos localizados en la interfaz entre la cadena variable y la cadena constante de un anticuerpo de longitud completa.
EP2216679A4 (en) LIGHT SOURCE FOR A PROJECTION SYSTEM AND PROJECTION DISPLAY DEVICE
AR056292A1 (es) Sistema y metodo para operar uno o mas dispensadores de combustible
EP2282188A4 (en) INSPECTION DEVICE AND METHOD FOR SPATIAL LIGHT MODULATOR, OPTICAL LIGHTING SYSTEM, METHOD FOR ADJUSTING THIS LIGHTING OPTICAL SYSTEM, EXPOSURE DEVICE, AND DEVICE MANUFACTURING METHOD
EP2372449A3 (en) Radiation source apparatus and DUV beam generation method
SG126866A1 (en) Dual stage lithographic apparatus and device manufacturing method
EA200802319A1 (ru) Способ и устройство для ремонта элементов конструкции
TW200714397A (en) Laser repair apparatus
DE602008006643D1 (de) Bildverarbeitungsverfahren
AR083747A1 (es) Anticuerpos anti-il-23
CR9869A (es) Compuestos activos en ppar
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
BRPI0811857A2 (pt) Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
SG139656A1 (en) Peripheral inspection system and method
WO2012118322A3 (ko) 격자패턴투영장치
ATE551199T1 (de) Bildverarbeitungsverfahren und bildverarbeitungsvorrichtung
TW200720062A (en) Rapid prototyping apparatus and method of rapid prototyping
TW200745842A (en) Securing scan test architecture
NL1035770A1 (nl) Lithographic apparatus and thermal optical manipulator control method.
NL1029728A1 (nl) Optische analyse-inrichting voor producten zoals fruit met beeldopname-inrichtingen aan weerszijden.
WO2011008688A3 (en) Scanner performance comparison and matching using design and defect data
EP2555228A4 (en) Light source apparatus, optical apparatus, exposure apparatus, device manufacturing method, illuminating method, exposure method, and method for manufacturing optical apparatus
AR055909A1 (es) Metodo y aparatos para sellar envases de lentes oftalmicas
BRPI0922058A2 (pt) método e dispositivo para comutação óptica.
ATE479157T1 (de) Scanverfahren und -vorrichtung